MT027 cells is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Phase 1. The lead sponsor is Suzhou Maximum Bio-tech Co., Ltd. The most-studied condition is Advanced Malignant Solid Tumor.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of MT027 in Patients with Pleural Malignant Tumors
NCT06726564 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma
|
Phase 1 | Recruiting | Suzhou Maximum Bio-tech Co., Ltd | China |
|
Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
NCT06737146 · ClinicalTrials.gov ↗ · High-grade Glioma
|
Phase 1 | Not yet open | Suzhou Maximum Bio-tech Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Suzhou Maximum Bio-tech Co., Ltd | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name MT027 cells as a drug or biological intervention, as of the registry sync on 29 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Suzhou Maximum Bio-tech Co., Ltd. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how MT027 cells works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how MT027 cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists MT027 cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 29 Sep 2026.